Generalizability of Progression Risk in the TN-10 Trial to a European Population With or Without a First-Degree Relative With Type 1 Diabetes
Time to progression to stage 3 appeared similar between the TN-10 placebo arm and the Fr1da group and between participants with and without FDRs with disease. Results suggest progression risk from the TN-10 trial may be generalizable to European populations with or without FDRs with type 1 diabetes.
Authors
- Christiane Winkler (ORCID: https://orcid.org/0000-0002-7606-3687)
- O Guenther
- Mark Yates (ORCID: https://orcid.org/0000-0001-5449-5211)
- Mireille Bonnemaire
- Anette‐Gabriele Ziegler (ORCID: https://orcid.org/0000-0002-6290-5548)
- Julia Zaccai (ORCID: https://orcid.org/0000-0001-8787-1789)
- Sandra Hummel (ORCID: https://orcid.org/0000-0001-6554-5974)
- Andreas Weiß (ORCID: https://orcid.org/0000-0001-9597-0576)
- Thibaut Koutangni (ORCID: https://orcid.org/0000-0002-1892-9112)
- Melanie Koeger
Institutions
- Ithaka Harbors (US)
- King's College London (GB)
- Center for Environmental Health (US)
- Sanofi (France) (FR)
- Helmholtz Zentrum München (DE)
- King's College School (GB)
- Deutsches Diabetes-Zentrum e.V. (DE)
- German Center for Diabetes Research (DE)
- Heinrich Heine University Düsseldorf (DE)
- Technical University of Munich (DE)
- Thermo Fisher Scientific (Israel) (IL)
Publication Details
- Journal
- Diabetes Care
- Published
- 2025-10-21
- DOI
- https://doi.org/10.2337/dc25-1021
- Citations
- 1
- Primary Topic
- Diabetes and associated disorders
- Type
- article
- Field-Weighted Citation Impact
- 1.82
Funders
- Sanofi
- Leona M. and Harry B. Helmsley Charitable Trust